Brickell Biotech, Inc. Made Big Gain
Tue, Jan 18, 2022 at 05:30 PM
Brickell Biotech, Inc. (BBI:NASDAQ) rocketted at $0.33, representing a gain of 58.6%. On Fri, Jan 14, 2022, BBI:NASDAQ touched a New 2-Week Low of $0.21. From Mon, Jan 03, 2022, the stock recorded 0.00% Up Days and 10.00% Green Days
About Brickell Biotech, Inc. (BBI:NASDAQ)
Brickell Biotech Inc is a United States-based clinical-stage pharmaceutical company focused on developing therapeutics for the treatment of skin diseases. Its pipeline consists of therapeutics for Hyperhidrosis, Cutaneous T-cell lymphoma, Psoriasis, and Other prevalent severe skin diseases. The company's pipeline products include Sofpironium Bromide, BBI-3000 and BBI-6000 among others.
Top 10 Gainers:
- Brickell Biotech, Inc. (BBI:NASDAQ), 58.58%
- DatChat Inc. (DATS:NASDAQ), 38.75%
- Indonesia Energy Corporation Limited (INDO:NYSEMKT), 31.1%
- NeuroMetrix, Inc. (NURO:NASDAQ), 29.47%
- Mainz Biomed B.V. (MYNZ:NASDAQ), 27.89%
- Vinco Ventures Inc. (BBIG:NASDAQ), 27.52%
- Activision Blizzard, Inc. (ATVI:NASDAQ), 25.88%
- Immuron Limited (IMRN:NASDAQ), 24.78%
- G Medical Innovations Holdings Ltd. (GMVD:NASDAQ), 20.29%
- Integrated Media Technology Limited (IMTE:NASDAQ), 19.95%